Participants 102 221 6
patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both
Participants 577 707 4
patients with systolic dysfunction and heart failure receiving therapeutic inhibition of the renin-angiotensin-aldosterone system.
Participants 888 1002 5
768 treated patients with heart failure measured at baseline and 17 and 43 weeks after randomization were examined
